Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) and keeping ...

GE HealthCare Technologies, Inc. GEHC announced that it has received FDA approval for Flyrcado (flurpiridaz F 18), a ...

Flyrcado is designed for patients with known or suspected CAD, providing a ready-to-use unit dose that can be manufactured ...

The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...

ARLINGTON HEIGHTS, Ill. - GE HealthCare (NASDAQ: NASDAQ:GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, a new positron emission ...

GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease ...

ARLINGTON HEIGHTS, Ill. - GE HealthCare (NASDAQ: NASDAQ:GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, a new positron emission ...

GE HealthCare has received approval for Flyrcado, its enhanced diagnosis tool for coronary heart disease, from the Food and Drug Administration. The company said on Friday that Flyrcado ...

GE Healthcare Technologies Inc. received U.S. FDA approval for its novel radiotracer, Flyrcado (flurpiridaz F-18), for use in ...

GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...

US FDA Approves GE HealthCare's Diagnostic Drug for Heart Disease (Reuters) - The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...